Neoleukin Therapeutics, Inc. — FY2019 Form 10-K
Entity note: The request identifies Neurogene Inc., but the supplied filing is for Neoleukin Therapeutics, Inc. (formerly Aquinox Pharmaceuticals, Inc.; Nasdaq: NLTX). It covers the fiscal year ended December 31, 2019, not solely Q4. The merger with Former Neoleukin closed August 8, 2019, so the year includes a major change in the company’s business and financial profile.
Business context and reporting period
Neoleukin is a preclinical biopharmaceutical company developing de novo protein immunotherapies for cancer, inflammation and autoimmunity. Its lead candidate, NL-201, is designed to mimic IL-2 and IL-15 activity while avoiding binding to the IL-2 receptor alpha subunit (CD25). The company reported encouraging preclinical findings for a precursor, but NL-201 had not entered human trials by year-end. It planned IND-enabling work and an IND submission by the end of 2020.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $0 | $25.0 million |
| Research and development expense | $4.4 million | $41.8 million |
| Acquired in-process R&D expense | $47.7 million | $0 |
| General and administrative expense | $18.8 million | $15.8 million |
| Total operating expenses | $71.0 million | $57.6 million |
| Net loss | $69.4 million | $31.6 million |
| Net loss per share, basic and diluted | $2.57 | $1.34 |
| Cash used in operating activities | $15.4 million | $31.6 million |
| Cash and cash equivalents at year-end | $143.1 million | $76.9 million |
| Working capital at year-end | $138.9 million | $72.5 million |
| Total liabilities at year-end | $5.3 million | $4.9 million |
There were no product sales, and margins are not meaningful for this pre-revenue company. The 2018 revenue was a non-refundable $25.0 million Astellas upfront payment for a rosiptor license and collaboration; that agreement was terminated in November 2018. The 2019 acquired in-process R&D charge arose from the merger and was expensed because management determined the asset had no alternative future use.
Financing activities provided $82.2 million in 2019, principally from a December public offering that generated $80.7 million net proceeds (10.26 million shares at $8.40 per share). Operating cash use fell from 2018, chiefly because rosiptor R&D had been halted and the prior-year restructuring reduced spending. The company had no material conventional borrowings disclosed; liabilities included operating and finance lease obligations. It reported $19.8 million of total contractual obligations, including $18.8 million of operating leases, and a new Seattle lease with rent beginning in December 2020.
Material changes versus the prior period
- Net loss more than doubled year over year, largely because of the $47.7 million merger-related acquired R&D charge; operating expenses excluding that charge also included higher G&A and the restart of NL-201 development.
- R&D expense declined sharply from 2018 because former Aquinox had suspended rosiptor development and restructuring reduced activity; Neoleukin R&D began after the August merger.
- Year-end cash rose by $66.2 million, mainly due to the December equity offering. Outstanding common shares increased to 38.0 million at year-end from 23.5 million a year earlier; 10.93 million shares were exchanged for pre-funded warrants in December.
- The transaction was accounted for as an asset acquisition, not a business combination. The merger consideration was $51.6 million, including securities issued and transaction costs.
Outlook, risks and unusual items
- Management’s operating plan indicated available cash and cash equivalents and marketable securities would fund operations and capital expenditure requirements through 2022. Elsewhere, the filing states resources were sufficient for at least the next 12 months; actual runway depends on development spending and other assumptions.
- NL-201 was still preclinical. Management planned to present preclinical data in the first half of 2020, complete IND-enabling toxicology work and submit an IND by year-end 2020. These were expectations, not guarantees.
- Management reported completion of GLP in-life toxicology dosing in rats and non-human primates with no unexpected toxicities observed. Human safety and efficacy remained untested; cytokine-related toxicity and immune reactions to novel de novo proteins were material risks.
- The company depends on third-party manufacturers and research vendors, has no commercial sales organization, and expects continued losses and additional capital needs. Competition in IL-2/IL-15 therapies is significant.
- The University of Washington license includes potential development and regulatory milestones of up to $0.9 million per distinct product class, commercial milestones up to $10.0 million per class, low-single-digit royalties and sharing of certain sublicense or transaction proceeds.
- The filing identified the emerging COVID-19 outbreak as a potential threat to suppliers, manufacturing and business operations; its impact could not then be estimated.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2019. The auditor did not attest to internal control effectiveness.
Most important facts for investors to verify
- Confirm that the filing being reviewed is Neoleukin’s, not Neurogene’s, and assess the post-merger financial and operating history accordingly.
- Track NL-201’s actual progress against the stated 2020 data and IND milestones, including toxicology, manufacturing readiness and regulatory status.
- Reconcile cash runway assumptions with quarterly operating cash use, planned clinical spending, the new facility lease and any subsequent financing.
- Review the merger accounting and the $47.7 million acquired R&D charge, as well as dilution from the offering, warrants and equity compensation.
- Assess the strength and scope of the licensed intellectual property, the UW agreement’s contingent economics, and competitive or safety developments in the IL-2/IL-15 field.